Outlook Therapeutics Inc (OTLK)
7.78
+0.45
(+6.14%)
USD |
NASDAQ |
May 17, 16:00
7.78
0.00 (0.00%)
After-Hours: 20:00
Outlook Therapeutics Free Cash Flow (Quarterly): -19.27M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -19.27M |
December 31, 2023 | -13.03M |
September 30, 2023 | -12.74M |
June 30, 2023 | -13.22M |
March 31, 2023 | -8.115M |
December 31, 2022 | -8.901M |
September 30, 2022 | -10.25M |
June 30, 2022 | -21.10M |
March 31, 2022 | -14.33M |
December 31, 2021 | -10.99M |
September 30, 2021 | -8.990M |
June 30, 2021 | -20.19M |
March 31, 2021 | -11.75M |
December 31, 2020 | -13.32M |
September 30, 2020 | -12.08M |
June 30, 2020 | -5.956M |
March 31, 2020 | -7.083M |
December 31, 2019 | -6.674M |
September 30, 2019 | -5.942M |
Date | Value |
---|---|
June 30, 2019 | -10.46M |
March 31, 2019 | -6.310M |
December 31, 2018 | -10.02M |
September 30, 2018 | -9.657M |
June 30, 2018 | -8.703M |
March 31, 2018 | -7.714M |
December 31, 2017 | -9.746M |
September 30, 2017 | 0.0559M |
June 30, 2017 | -5.709M |
March 31, 2017 | -4.154M |
December 31, 2016 | -5.99M |
September 30, 2016 | -10.70M |
June 30, 2016 | -16.49M |
March 31, 2016 | -7.011M |
December 31, 2015 | -12.38M |
September 30, 2015 | -14.31M |
June 30, 2015 | -13.53M |
March 31, 2015 | -4.253M |
December 31, 2014 | -4.194M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-21.10M
Minimum
Jun 2022
-5.942M
Maximum
Sep 2019
-11.72M
Average
-11.37M
Median
Free Cash Flow (Quarterly) Benchmarks
Cutera Inc | -37.96M |
Actinium Pharmaceuticals Inc | -7.385M |
GT Biopharma Inc | -2.047M |
Karyopharm Therapeutics Inc | -43.92M |
Marinus Pharmaceuticals Inc | -37.46M |